{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:58:38Z","timestamp":1762955918550},"reference-count":60,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Med Report"],"DOI":"10.3892\/mmr.2018.9219","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T10:11:50Z","timestamp":1529921510000},"source":"Crossref","is-referenced-by-count":4,"title":["Intraperitoneal oxaliplatin administration inhibits the tumor immunosuppressive microenvironment in an abdominal implantation model of colon cancer"],"prefix":"10.3892","author":[{"given":"Hong\u2011Feng","family":"Gou","sequence":"first","affiliation":[{"name":"Department of Abdominal Cancer, Cancer Center, The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Abdominal Cancer, Cancer Center, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Abdominal Cancer, Cancer Center, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin\u2011Chuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2018,6,25]]},"reference":[{"key":"key20200713230333_b1-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J Exp Med"},{"key":"key20200713230333_b2-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The secret ally: Immunostimulation by anticancer drugs","volume":"11","author":"Galluzzi","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"key20200713230333_b3-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4161\/onci.1.1.17930","article-title":"Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin","volume":"1","author":"Hernandez-Alcoceba","year":"2012","journal-title":"Oncoimmunology"},{"key":"key20200713230333_b4-mmr-18-02-2335","first-page":"2127","article-title":"Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects","volume":"119","author":"Zitvogel","year":"2009","journal-title":"J Clin Invest"},{"key":"key20200713230333_b5-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrc1613","article-title":"Immunotherapy and chemotherapy-a practical partnership","volume":"5","author":"Lake","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"key20200713230333_b6-mmr-18-02-2335","first-page":"2353","article-title":"Gemcitabine exerts a selective effect on the humoral immune response: Implications for combination chemo-immunotherapy","volume":"62","author":"Nowak","year":"2002","journal-title":"Cancer Res"},{"key":"key20200713230333_b7-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nri2545","article-title":"Immunogenic and tolerogenic cell death","volume":"9","author":"Green","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"key20200713230333_b8-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/cdd.2011.96","article-title":"Molecular definitions of cell death subroutines: Recommendations of the nomenclature committee on cell death 2012","volume":"19","author":"Galluzzi","year":"2012","journal-title":"Cell Death Differ"},{"key":"key20200713230333_b9-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: Reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"},{"key":"key20200713230333_b10-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","article-title":"Exploring the full spectrum of macrophage activation","volume":"8","author":"Mosser","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"key20200713230333_b11-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res"},{"key":"key20200713230333_b12-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"key":"key20200713230333_b13-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s10637-010-9598-9","article-title":"Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer","volume":"30","author":"Madajewicz","year":"2012","journal-title":"Invest New Drugs"},{"key":"key20200713230333_b14-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.clim.2008.07.013","article-title":"Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy","volume":"129","author":"Zhang","year":"2008","journal-title":"Clin Immunol"},{"key":"key20200713230333_b15-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"key":"key20200713230333_b16-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1158\/1078-0432.CCR-10-0733","article-title":"A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers","volume":"16","author":"Kodumudi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20200713230333_b17-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20200713230333_b18-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1158\/0008-5472.CAN-13-3596","article-title":"Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis","volume":"74","author":"Ding","year":"2014","journal-title":"Cancer Res"},{"key":"key20200713230333_b19-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-14-0657","article-title":"Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes","volume":"74","author":"Kanterman","year":"2014","journal-title":"Cancer Res"},{"key":"key20200713230333_b20-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1158\/0008-5472.CAN-12-3542","article-title":"Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment","volume":"73","author":"Dijkgraaf","year":"2013","journal-title":"Cancer Res"},{"key":"key20200713230333_b21-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrd1287","article-title":"Oxaliplatin","volume":"3","author":"Graham","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"key20200713230333_b22-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"key20200713230333_b23-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/jso.23431","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer","volume":"108","author":"Gervais","year":"2013","journal-title":"J Surg Oncol"},{"key":"key20200713230333_b24-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20200713230333_b25-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1365-2567.2010.03357.x","article-title":"Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages","volume":"132","author":"Buhtoiarov","year":"2011","journal-title":"Immunology"},{"key":"key20200713230333_b26-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"key20200713230333_b27-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2009-01-200931","article-title":"A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood \u2018resident\u2019 monocytes, and embryonic macrophages suggests common functions and developmental relationships","volume":"114","author":"Pucci","year":"2009","journal-title":"Blood"},{"key":"key20200713230333_b28-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"key20200713230333_b29-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1158\/0008-5472.CAN-10-2670","article-title":"Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice","volume":"71","author":"Mundy-Bosse","year":"2011","journal-title":"Cancer Res"},{"key":"key20200713230333_b30-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2051-1426-1-10","article-title":"Myeloid derived suppressor cells-a new therapeutic target in the treatment of cancer","volume":"1","author":"Wesolowski","year":"2013","journal-title":"J Immunother Cancer"},{"key":"key20200713230333_b31-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1158\/0008-5472.CAN-14-0301","article-title":"Chemotherapeutic targeting of cancer-induced immunosuppressive cells","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res"},{"key":"key20200713230333_b32-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri1936","article-title":"Cancer despite immunosurveillance: Immunoselection and immunosubversion","volume":"6","author":"Zitvogel","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"key20200713230333_b33-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nrc2250","article-title":"Regulatory-T-cell inhibition versus depletion: The right choice in cancer immunotherapy","volume":"7","author":"Colombo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"key20200713230333_b34-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: Harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"key20200713230333_b35-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"key20200713230333_b36-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1172\/JCI30414","article-title":"Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells","volume":"117","author":"Wrzesinski","year":"2007","journal-title":"J Clin Invest"},{"key":"key20200713230333_b37-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"key20200713230333_b38-mmr-18-02-2335","first-page":"3303","article-title":"Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma","volume":"18","author":"Sun","year":"2012","journal-title":"World J Gastroenterol"},{"key":"key20200713230333_b39-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.semcancer.2012.02.008","article-title":"New insights into chronic inflammation-induced immunosuppression","volume":"22","author":"Kanterman","year":"2012","journal-title":"Semin Cancer Biol"},{"key":"key20200713230333_b40-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3109\/1547691X.2011.642418","article-title":"Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner","volume":"9","author":"Michels","year":"2012","journal-title":"J Immunotoxicol"},{"key":"key20200713230333_b41-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1158\/0008-5472.CAN-11-0753","article-title":"Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors","volume":"71","author":"Mattarollo","year":"2011","journal-title":"Cancer Res"},{"key":"key20200713230333_b42-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/1479-5876-9-216","article-title":"Identification and manipulation of tumor associated macrophages in human cancers","volume":"9","author":"Heusinkveld","year":"2011","journal-title":"J Transl Med"},{"key":"key20200713230333_b43-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: In vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J Clin Invest"},{"key":"key20200713230333_b44-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1084\/jem.20082173","article-title":"Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1","volume":"206","author":"Kuang","year":"2009","journal-title":"J Exp Med"},{"key":"key20200713230333_b45-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/jcp.24260","article-title":"Tumor associated macrophages and neutrophils in tumor progression","volume":"228","author":"Galdiero","year":"2013","journal-title":"J Cell Physiol"},{"key":"key20200713230333_b46-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.lungcan.2013.02.017","article-title":"Tumor-associated macrophages in thoracic malignancies","volume":"80","author":"Lievense","year":"2013","journal-title":"Lung Cancer"},{"key":"key20200713230333_b47-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s10120-014-0422-7","article-title":"Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection","volume":"18","author":"Zhang","year":"2015","journal-title":"Gastric Cancer"},{"key":"key20200713230333_b48-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1757-2215-7-19","article-title":"A high M1\/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients","volume":"7","author":"Zhang","year":"2014","journal-title":"J Ovarian Res"},{"key":"key20200713230333_b49-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.ejca.2006.01.003","article-title":"Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy","volume":"42","author":"Sica","year":"2006","journal-title":"Eur J Cancer"},{"key":"key20200713230333_b50-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/imm.12023","article-title":"Anti-tumour strategies aiming to target tumour-associated macrophages","volume":"138","author":"Tang","year":"2013","journal-title":"Immunology"},{"key":"key20200713230333_b51-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: A single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20200713230333_b52-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1479-5876-4-21","article-title":"Monocyte\/macrophage and T-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic disease","volume":"4","author":"Wang","year":"2006","journal-title":"J Transl Med"},{"key":"key20200713230333_b53-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1158\/0008-5472.CAN-06-4375","article-title":"Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice","volume":"67","author":"Robinson-Smith","year":"2007","journal-title":"Cancer Res"},{"key":"key20200713230333_b54-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ajpath.2013.09.017","article-title":"Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype","volume":"184","author":"Ko","year":"2014","journal-title":"Am J Pathol"},{"key":"key20200713230333_b55-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1158\/0008-5472.CAN-06-4410","article-title":"Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression","volume":"67","author":"Bak","year":"2007","journal-title":"Cancer Res"},{"key":"key20200713230333_b56-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.immuni.2009.04.010","article-title":"Mechanisms of foxp3+ T regulatory cell-mediated suppression","volume":"30","author":"Shevach","year":"2009","journal-title":"Immunity"},{"key":"key20200713230333_b57-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur J Immunol"},{"key":"key20200713230333_b58-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s00262-009-0671-1","article-title":"Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model","volume":"58","author":"Banissi","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"key20200713230333_b59-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/gut.2010.211722","article-title":"Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice","volume":"60","author":"Gonzalez-Aparicio","year":"2011","journal-title":"Gut"},{"key":"key20200713230333_b60-mmr-18-02-2335","doi-asserted-by":"publisher","first-page":"e85789","DOI":"10.1371\/journal.pone.0085789","article-title":"Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice","volume":"9","author":"Gou","year":"2014","journal-title":"PLoS One"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T23:02:01Z","timestamp":1594681321000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mmr.2018.9219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,25]]},"references-count":60,"URL":"https:\/\/doi.org\/10.3892\/mmr.2018.9219","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,25]]}}}